Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop ...

This will be Maharashtra’s first public hospital where not just cancer, but also inherited blood disorders in both children ...

ISB 2001, a first-in-class trispecific antibody developed by IGI, showed a 79% response rate in relapsed/refractory multiple ...

In the front row, Dr. Bruno Paiva, with the team from the Multiple Myeloma Group at Cima and the Clínica Universidad de ...

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk of developing ...

At 38, author Jonathan Gluck was diagnosed with blood cancer and given less than three years to live. He's written a memoir ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

Facing a rare cancer and mounting medical costs, Gregory Morgan is turning to his community for support in his fight for life ...